Public health effects of adult pneumococcal vaccination choice amid increased serotype 4 rates in US subpopulations.

ABSTRACT:

Objectives

Pneumococcal serotype 4 illness surged among some US Native American and homeless populations. The impact of potential serotype 4 rate increases on US adult pneumococcal conjugate vaccine (PCV) options is unclear.

Study design

Decision analysis.

Methods

A Markov model estimated differences in public health effects in US 50- and 65-year-old cohorts between 21-valent PCV (PCV21), which does not contain serotype 4, and 20-valent PCV (PCV20), which does contain it, tracking outcome differences resulting from serotype 4 illness rate increases from 0 to 6 per 100,000 over baseline annual rates. CDC data informed vaccine serotype-specific pneumococcal disease risks. Model parameters were varied in deterministic and probabilistic sensitivity analyses.

Results

SUBMITTER: Smith KJ 

PROVIDER: S-EPMC12757742 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature